Compagnie Lombard Odier S Cm A Editas Medicine, Inc. Transaction History

Compagnie Lombard Odier S Cm A

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	BUY	$6.92 - $9.31 $0 - $0	0 New	0 $0
Q3 2021 Oct 28, 2021	SELL	$39.27 - $72.94 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 15, 2021	SELL	$31.29 - $56.64 $5.92 Million - $10.7 Million	-189,294 Closed	0 $0
Q1 2021 Apr 23, 2021	BUY	$39.71 - $90.58 $7.51 Million - $17.1 Million	189,194 Added 189194.0%	189,294 $7.95 Million
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1,850 - $3,434	100 New	100 $3,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.